Global Commercializing Biomarkers Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Commercializing Biomarkers Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Biomarkers measure cellular, biochemical or molecular changes in human tissues, cells or fluids, and contribute to future diagnostics and treatment. The development of biomarkers is time consuming and expensive, requiring the involvement of industry from early stages to better direct the research.
Commercializing Biomarkers report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Commercializing Biomarkers market is projected to reach US$ 29560 million in 2029, increasing from US$ 21390 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Demand from Oncology and Cardiology are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Commercializing Biomarkers industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Commercializing Biomarkers key manufacturers include Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia and ALMAC, etc. Roche, Dako (Agilent Technologies), Merck are top 3 players and held % sales share in total in 2022.
Commercializing Biomarkers can be divided into Consumables, Services and Software,, etc. Consumables is the mainstream product in the market, accounting for % sales share globally in 2022.
Commercializing Biomarkers is widely used in various fields, such as Oncology, Cardiology, Neurology and Others, etc. Oncology provides greatest supports to the Commercializing Biomarkers industry development. In 2022, global % sales of Commercializing Biomarkers went into Oncology filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Commercializing Biomarkers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Oncology
Cardiology
Neurology
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Commercializing Biomarkers market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Commercializing Biomarkers, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Commercializing Biomarkers industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Commercializing Biomarkers in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Commercializing Biomarkers introduction, etc. Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Commercializing Biomarkers market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Commercializing Biomarkers report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Commercializing Biomarkers market is projected to reach US$ 29560 million in 2029, increasing from US$ 21390 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Demand from Oncology and Cardiology are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Commercializing Biomarkers industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Commercializing Biomarkers key manufacturers include Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia and ALMAC, etc. Roche, Dako (Agilent Technologies), Merck are top 3 players and held % sales share in total in 2022.
Commercializing Biomarkers can be divided into Consumables, Services and Software,, etc. Consumables is the mainstream product in the market, accounting for % sales share globally in 2022.
Commercializing Biomarkers is widely used in various fields, such as Oncology, Cardiology, Neurology and Others, etc. Oncology provides greatest supports to the Commercializing Biomarkers industry development. In 2022, global % sales of Commercializing Biomarkers went into Oncology filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Commercializing Biomarkers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Commercializing Biomarkers market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Commercializing Biomarkers, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Commercializing Biomarkers industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Commercializing Biomarkers in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Commercializing Biomarkers introduction, etc. Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Commercializing Biomarkers market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices